Literature DB >> 26120211

Synthesis and bioactivity of MSH4 oligomers prepared by an A2 + B2 strategy.

Dilani Chathurika Dehigaspitiya1, Suryakiran Navath1, Craig S Weber2, Ronald M Lynch3, Eugene A Mash1.   

Abstract

Oligomers incorporating the tetrapeptide MSH4, the minimum active sequence of melanocyte stimulating hormone, were synthesized by an A2 + B2 strategy involving microwave-assisted copper-catalyzed azide-alkyne cycloaddition. A2 contained an MSH4 core while B2 contained a (Pro-Gly)3 spacer. Soluble mixtures containing compounds with up to eight MSH4 units were obtained from oligomerizations at high monomer concentrations. The avidities of several oligomeric mixtures were evaluated by means of a competitive binding assay using HEK293 cells engineered to overexpress the melanocortin 4 receptor. When based on total MSH4 concentrations, avidities were only minimally enhanced compared with a monovalent control. The lack of variation in the effect of ligands on probe binding is consistent with high off rates for MSH4 in both monovalent and oligomeric constructs relative to that of the competing probe.

Entities:  

Keywords:  Competitive binding assay; Melanocortin 4 receptor; Multivalent ligand; Oligomerization; Time-resolved fluorescence

Year:  2015        PMID: 26120211      PMCID: PMC4480789          DOI: 10.1016/j.tetlet.2014.12.022

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN: 0040-4039            Impact factor:   2.415


  42 in total

1.  On the nature of the multivalency effect: a thermodynamic model.

Authors:  Pavel I Kitov; David R Bundle
Journal:  J Am Chem Soc       Date:  2003-12-31       Impact factor: 15.419

2.  Fluorescent and lanthanide labeling for ligand screens, assays, and imaging.

Authors:  Jatinder S Josan; Channa R De Silva; Byunghee Yoo; Ronald M Lynch; Mark D Pagel; Josef Vagner; Victor J Hruby
Journal:  Methods Mol Biol       Date:  2011

3.  Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment.

Authors:  Nabila Brabez; Ronald M Lynch; Liping Xu; Robert J Gillies; Gerard Chassaing; Solange Lavielle; Victor J Hruby
Journal:  J Med Chem       Date:  2011-10-03       Impact factor: 7.446

4.  Heterobivalent ligands target cell-surface receptor combinations in vivo.

Authors:  Liping Xu; Jatinder S Josan; Josef Vagner; Michael R Caplan; Victor J Hruby; Eugene A Mash; Ronald M Lynch; David L Morse; Robert J Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-10       Impact factor: 11.205

5.  A solanesol-derived scaffold for multimerization of bioactive peptides.

Authors:  Ramesh Alleti; Venkataramanarao Rao; Liping Xu; Robert J Gillies; Eugene A Mash
Journal:  J Org Chem       Date:  2010-09-03       Impact factor: 4.354

6.  Melanoma imaging with pretargeted bivalent bacteriophage.

Authors:  Jessica R Newton; Yubin Miao; Susan L Deutscher; Thomas P Quinn
Journal:  J Nucl Med       Date:  2007-03       Impact factor: 10.057

7.  Synthesis and evaluation of bivalent NDP-alpha-MSH(7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R).

Authors:  Heather L Handl; Rajesh Sankaranarayanan; Jatinder S Josan; Josef Vagner; Eugene A Mash; Robert J Gillies; Victor J Hruby
Journal:  Bioconjug Chem       Date:  2007-06-26       Impact factor: 4.774

8.  Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors.

Authors:  Ramesh Alleti; Josef Vagner; Dilani Chathurika Dehigaspitiya; Valerie E Moberg; N G R D Elshan; Narges K Tafreshi; Nabila Brabez; Craig S Weber; Ronald M Lynch; Victor J Hruby; Robert J Gillies; David L Morse; Eugene A Mash
Journal:  Bioorg Med Chem       Date:  2013-07-02       Impact factor: 3.641

9.  The melanocortin 4 receptor: oligomer formation, interaction sites and functional significance.

Authors:  Kathryn L Chapman; John B C Findlay
Journal:  Biochim Biophys Acta       Date:  2012-10-23

10.  Evaluation of the human melanoma targeting properties of radiolabeled alpha-melanocyte stimulating hormone peptide analogues.

Authors:  Yubin Miao; Donna Whitener; Weiwei Feng; Nellie K Owen; Jianqing Chen; Thomas P Quinn
Journal:  Bioconjug Chem       Date:  2003 Nov-Dec       Impact factor: 4.774

View more
  4 in total

Review 1.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

2.  Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2018-05-09       Impact factor: 7.446

3.  A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.

Authors:  Cody J Lensing; Danielle N Adank; Stacey L Wilber; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2017-02-16       Impact factor: 4.418

4.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2016-03-29       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.